EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TRP-2 / gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors

Joshua R D Pearson, Carles Puig-Saenz, Jubini E Thomas, Lydia D Hardowar, Murrium Ahmad, Louise C Wainwright, Adam M McVicar, Victoria A Brentville, Chris J Tinsley, A Graham Pockley, Lindy G Durrant, Stephanie E B McArdle

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03770-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Joshua R D Pearson und 11 weiteren Autor:innen. Beteiligte Einrichtung: John Van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, UK. Hauptthemen laut MEDLINE: Brain Neoplasms, Cancer Vaccines, Immune Checkpoint Inhibitors, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Headcase Cancer Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intracranial tumors present a significant therapeutic challenge due to their physiological location. Immunotherapy presents an attractive method for targeting these intracranial tumors due to relatively low toxicity and tumor specificity. Here we show that SCIB1, a TRP-2 and gp100 directed ImmunoBody® DNA vaccine, generates a strong TRP-2 specific immune response, as demonstrated by the high number of TRP2-specific IFNγ spots produced and the detection of a significant number of pentamer positive T cells in the spleen of vaccinated mice. Furthermore, vaccine-induced T cells were able to recognize and kill B16 HHDII/DR1 cells after a short in vitro culture. Having found that glioblastoma multiforme (GBM) expresses significant levels of PD-L1 and IDO1 , with PD-L1 correlating with poorer survival in patients with the mesenchymal subtype of GBM, we decided to combine SCIB1 ImmunoBody® with PD-1 immune checkpoint blockade to treat mice harboring intracranial tumors expressing TRP-2 and gp100. Time-to-death was significantly prolonged, and this correlated with increased CD4 + and CD8 + T cell infiltration in the tissue microenvironment (TME). However, in addition to PD-L1 and IDO, the GBM TME was found to contain a significant number of immunoregulatory T (Treg) cell-associated transcripts, and the presence of such cells is likely to significantly affect clinical outcome unless also tackled.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsCancer VaccinesImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorVaccines, DNAAnimalsFemaleHumansMiceB7-H1 AntigenCell Line, TumorGlioblastomaImmunotherapyIntramolecular OxidoreductasesMice, Inbred C57BLMaleChildMiddle Aged

Stichwörter der Autor:innen

Brain tumorCancer vaccineGlioblastoma multiformeImmune checkpoint blockadePD-1TRP-2

Substanzen

B7-H1 AntigenCancer Vaccinesdopachrome isomeraseImmune Checkpoint InhibitorsIntramolecular OxidoreductasesProgrammed Cell Death 1 ReceptorVaccines, DNA

Autor:innen und Institutionen

  • John Van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, UK.
  • Department of Biosciences, School of Science and Technology, Nottingham Trent University, Nottingham, UK.
  • Bioscience Support Facility, School of Science and Technology, Nottingham Trent University, Nottingham, UK.
  • Scancell Ltd, Unit 202, Bellhouse Building, Oxford Science Park, Sanders Road, Oxford, OX4 4GA, UK.
  • John Van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, UK. stephanie.mcardle@ntu.ac.uk.

Förderung

  • Headcase Cancer Trust

Zitieren

APA

Pearson, J. R. D., Puig-Saenz, C., Thomas, J. E., Hardowar, L. D., Ahmad, M., Wainwright, L. C., McVicar, A. M., Brentville, V. A., Tinsley, C. J., Pockley, A. G., Durrant, L. G., & McArdle, S. E. B. (2024). TRP-2 / gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03770-x

Vancouver

Pearson JRD, Puig-Saenz C, Thomas JE, Hardowar LD, Ahmad M, Wainwright LC, et al. TRP-2 / gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03770-x

BibTeX
@article{Pearson2024,
  author = {Pearson, Joshua R D and Puig-Saenz, Carles and Thomas, Jubini E and Hardowar, Lydia D and Ahmad, Murrium and Wainwright, Louise C and McVicar, Adam M and Brentville, Victoria A and Tinsley, Chris J and Pockley, A Graham and Durrant, Lindy G and McArdle, Stephanie E B},
  title = {TRP-2 / gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03770-x}
}
Kostenlos starten →